Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
C4 Therapeutics, Inc. (NASDAQ: CCCC) is now covered by analysts at Stephens. They set an "equal weight" rating and a $4.00 price target on the stock.
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial